| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MYO1D |
| Uniprot No | O94832 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-1006aa |
| 氨基酸序列 | MAEQESLEFGKADFVLMDTVSMPEFMANLRLRFEKGRIYTFIGEVVVSVNPYKLLNIYGRDTIEQYKGRELYERPPHLFAIADAAYKAMKRRSKDTCIVISGESGAGKTEASKYIMQYIAAITNPSQRAEVERVKNMLLKSNCVLEAFGNAKTNRNDNSSRFGKYMDINFDFKGDPIGGHINNYLLEKSRVIVQQPGERSFHSFYQLLQGGSEQMLRSLHLQKSLSSYNYIHVGAQLKSSINDAAEFRVVADAMKVIGFKPEEIQTVYKILAAILHLGNLKFVVDGDTPLIENGKVVSIIAELLSTKTDMVEKALLYRTVATGRDIIDKQHTEQEASYGRDAFAKAIYERLFCWIVTRINDIIEVKNYDTTIHGKNTVIGVLDIYGFEIFDNNSFEQFCINYCNEKLQQLFIQLVLKQEQEEYQREGIPWKHIDYFNNQIIVDLVEQQHKGIIAILDDACMNVGKVTDEMFLEALNSKLGKHAHFSSRKLCASDKILEFDRDFRIRHYAGDVVYSVIGFIDKNKDTLFQDFKRLMYNSSNPVLKNMWPEGKLSITEVTKRPLTAATLFKNSMIALVDNLASKEPYYVRCIKPNDKKSPQIFDDERCRHQVEYLGLLENVRVRRAGFAFRQTYEKFLHRYKMISEFTWPNHDLPSDKEAVKKLIERCGFQDDVAYGKTKIFIRTPRTLFTLEELRAQMLIRIVLFLQKVWRGTLARMRYKRTKAALTIIRYYRRYKVKSYIHEVARRFHGVKTMRDYGKHVKWPSPPKVLRRFEEALQTIFNRWRASQLIKSIPASDLPQVRAKVAAVEMLKGQRADLGLQRAWEGNYLASKPDTPQTSGTFVPVANELKRKDKYMNVLFSCHVRKVNRFSKVEDRAIFVTDRHLYKMDPTKQYKVMKTIPLYNLTGLSVSNGKDQLVVFHTKDNKDLIVCLFSKQPTHESRIGELVGVLVNHFKSEKRHLQVNVTNPVQCSLHGKKCTVSVETRLNQPQPDFTKNRSGFILSVPGN |
| 预测分子量 | 116,2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Recombinant MYO1D regulates epithelial cell polarity through interaction with apical scaffolding proteins"**
- 作者：Tanaka et al.
- 摘要：研究通过重组MYO1D蛋白在体外模型中的表达，揭示其通过与顶端膜支架蛋白(如CRB3)的相互作用，调控上皮细胞极性的建立和维持。
2. **"Expression and functional characterization of MYO1D in intracellular vesicle trafficking"**
- 作者：Smith & Johnson
- 摘要：利用重组MYO1D蛋白进行体外实验，证明其通过肌动蛋白结合域参与内体运输，影响溶酶体定位及分泌途径的调控。
3. **"MYO1D gene cloning and its role in left-right asymmetry development"**
- 作者：Lee et al.
- 摘要：通过重组MYO1D在小鼠胚胎中的过表达，发现其调控纤毛运动及胚胎左右体轴形成的分子机制，可能与先天性发育缺陷相关。
4. **"Structural analysis of MYO1D reveals a unique cargo-binding domain"**
- 作者：Chen et al.
- 摘要：通过重组MYO1D蛋白的晶体结构解析，发现其C端存在新型货物结合域，为理解其与特定细胞器(如高尔基体)的相互作用提供结构基础。
MYO1D, a member of the myosin superfamily, is an actin-based motor protein involved in intracellular trafficking, cell polarization, and mechanical signaling. As a class I myosin, it consists of a conserved N-terminal motor domain that binds actin and hydrolyzes ATP, a neck region with IQ motifs for calmodulin/light-chain binding, and a C-terminal tail domain mediating membrane interactions. MYO1D plays unique roles in establishing left-right asymmetry during embryonic development and regulating vesicle transport in polarized cells, such as epithelial and neuronal cells. Its dysfunction has been linked to developmental disorders and cancer metastasis.
Recombinant MYO1D protein is typically produced using heterologous expression systems (e.g., baculovirus/insect cells or mammalian cell lines) to ensure proper post-translational modifications. The purified protein often includes affinity tags (e.g., His-tag or GST-tag) for isolation via nickel-affinity or glutathione chromatography. Researchers utilize this recombinant form to study MYO1D's mechanochemical properties, binding partners (e.g., actin filaments, PIP2 lipids), and regulatory mechanisms through in vitro motility assays, single-molecule studies, and structural analyses (cryo-EM or X-ray crystallography). It also serves as a critical reagent for screening small-molecule modulators and investigating MYO1D's role in cellular processes like apical constriction, ciliogenesis, and planar cell polarity. Recent studies highlight its potential as a therapeutic target for laterality defects and metastatic cancers, driving increased demand for high-purity recombinant MYO1D in both basic and translational research.
×
